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Abstract. Telomerase is a cellular ribonucleoprotein reverse 
transcriptase that plays a crucial role in telomere maintenance. 
This enzyme is expressed in approximately 90% of human 
tumors, but not in the majority of normal somatic cells. 
Imetelstat sodium (GRN163L), is a 13-mer oligonucleotide 
N3'→P5' thio-phosphoramidate lipid conjugate, which repre-
sents the latest generation of telomerase inhibitors targeting 
the template region of the human functional telomerase RNA 
(hTR) subunit. In preclinical trials, this compound has been 
found to inhibit telomerase activity in multiple cancer cell 
lines, as well as in vivo xenograft mouse models. Currently, 
GRN163L is being investigated in several clinical trials, 
including a phase II human non-small cell lung cancer clinical 
trial, in a maintenance setting following standard doublet 
chemotherapy. In addition to the inhibition of telomerase 
activity in cancer cell lines, GRN163L causes morphological 
cell rounding changes, independent of hTR expression or telo-
mere length. This leads to the loss of cell adhesion properties; 
however, the mechanism underlying this effect is not yet fully 
understood. In the present study, we observed that GRN163L 
treatment leads to the loss of adhesion in A549 lung cancer 
cells, due to decreased E-cadherin expression, leading to the 
disruption of the cytoskeleton through the alteration of actin, 
tubulin and intermediate filament organization. Consequently, 
the less adherent cancer cells initially cease to proliferate and 
are arrested in the G1 phase of the cell cycle, accompanied by 
decreased matrix metalloproteinase-2 (MMP-2) expression. 
These effects of GRN163L are independent of its telomerase 
catalytic activity and may increase the therapeutic efficacy of 
GRN163L by decreasing the adhesion, proliferation and meta-
static potential of cancer cells in vivo.
Introduction
Non-small cell lung cancer (NSCLC) is the most common cause 
of cancer-related mortality. Doublet combination chemotherapy 
is currently the first-line therapy for advanced lung cancer that 
is not surgically resectable. However, even with chemotherapy, 
the prognosis of patients with advanced NSCLC remains poor, 
with a 1-year survival rate of 30% (1,2). Therefore, it is impor-
tant to develop new treatment regimens in order to reduce the 
morbidity and mortality of this fatal disease.
Telomeres are DNA repeats (TTAGGG)n found at the end 
of chromosomes, and play an important role in maintaining 
genomic stability (3,4). Due to the end replication problem, 
telomeres are progressively lost with each cell division, 
eventually leading to cell growth arrest (replicative senes-
cence) in normal cells (5,6). Critical telomere shortening 
may be considered as an initial block to indefinite cellular 
proliferation (a hallmark of cancer). However, telomere short-
ening may be counteracted by the cellular ribonucleoprotein 
reverse-transcriptase telomerase (hTERT), which uses a part 
of an internal RNA moiety as a template for the synthesis 
of telomeric repeats (7,8). Telomerase activity is not readily 
detectable in most quiescent normal somatic tissues; it is, 
however, highly expressed in ~90% of human tumors. This 
feature renders this enzyme an attractive, almost universal, 
target for cancer therapy. Therefore, various telomerase 
inhibitors have been developed over the past few years (9,10). 
Among these compounds, a thio-phosphoramidate oligo-
nucleotide, imetelstat sodium (GRN163L), is being assessed 
in clinical trials as a potent human telomerase inhibitor. This 
molecule was designed as a competitive telomerase inhibitor, 
which binds directly to the active site of the enzyme, thus inhi-
biting its activity. The presence of the covalently conjugated 
5'-palmitoyl (C16) lipid group provides more effective cellular 
uptake and increased bioavailability of GRN163L (11,12). This 
compound is currently in multiple phase II clinical trials as a 
potential broad-spectrum anticancer agent.
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Our previous in vitro studies showed that GRN163L 
effectively inhibits telomerase activity in A549 lung cancer 
cells, reduces their proliferation rate within 3-4 weeks and 
progressively shortens telomere length in 5-6 weeks, leading 
to apoptotic cell death. Moreover, GRN163L effectively 
inhibits the formation and growth of lung metastases in xeno-
graft animal models in vivo (13). We have also reported that 
A549 cells treated with a single dose of GRN163L (1 µM) 
prior to cell attachment, were relatively weakly attached to 
the plate surface substrates and were morphologically altered 
(i.e., became rounded), whereas mismatch (MM) control-
treated cells exhibited a typical epithelioid appearance and 
normal adhesion properties. These morphological changes 
were independent of human telomerase RNA (hTR) subunit 
expression or telomerase inhibition and were unrelated to 
telomere length. We determined that these effects were due 
to the molecular structure of the oligo thio-phosphoramidate 
and its lipid moiety, the N3'→P5'-thio-phosphoramidate 
backbone and the presence of G-quadruplex-forming triple-
G sequences within the GRN163L (14). However, the exact 
mechanism underlying these morphological changes remains 
unknown.
Microfilaments, microtubules and intermediate fila-
ments are fundamental structures of the cytoskeleton, which 
play important roles in the determination of cell shape, 
proliferation and migration. F-actin filaments are required 
for cell shape determination, microtubules are responsible 
for the positioning of organelles playing a pivotal role in 
intracellular transport and intermediate filaments provide 
mechanical support and resistance to stress (15). Cadherins are 
Ca2+-dependent adhesion molecules. One of the most widely 
investigated is E-cadherin, which influences cellular shape 
and cell-cell interactions. The loss of E-cadherin-mediated 
adhesion is considered to be characteristic of the transition 
from benign lesions to invasive and metastatic cancer (16). In 
the present study, we investigated whether the cytoskeletal and 
cell adhesion proteins are associated with the observed rapid 
morphological alterations (i.e., ‘rounding effect’) and the loss 
of adhesion of A549 lung cancer cells treated with a single 
dose of GRN163L (1 µM). In addition, since it has been shown 
that the overexpression of telomerase in cancer cells increases 
the level of matrix metalloproteinase-2 (MMP-2), which is 
directly involved in the invasion process (17), we observed 
that GRN163L decreased MMP-2 expression, suggesting that 
GRN163L exerts some of its anticancer effects in a telomere-
independent manner.
Materials and methods
Cell culture. A549 non-small lung cancer cells were obtained 
from the American Type Culture Collection (ATCC; Manassas, 
VA, USA). A549 cells were cultured in DMEM containing 
10% fetal bovine serum (FBS; Sigma, St. Louis, MO, USA) 
and 100 U̸ml penicillin-streptomycin (Sigma). The 13-mer 
GRN163L (Geron Corp., Menlo Park, CA, USA), which comple-
ments the template region of telomerase hTR (also known as 
hTERC), and the MM control oligonucleotide, which does not 
complement the template region of hTR, were prepared as previ-
ously described (11).
Western blot analysis. The A549 cells (1x106) were plated 
in 6-well plates and immediately treated with MM (1 µM) or 
GRN163L (1 µM). The untreated control and treated cells were 
collected following a 24-h incubation period and lysed with NP-40 
lysis buffer containing 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 
1% NP-40 detergent and 1X protease inhibitor complex (Roche 
Applied Science, Indianapolis, IN, USA). Protein concentration 
was quantified using the Bradford assay (Sigma), as previously 
described (12). A total of 40 µg of protein lysate was subjected to 
SDS-PAGE, followed by transfer onto polyvinylidene difluoride 
membranes. Blocking and antibody incubation were performed 
in 5% milk in PBS containing 0.2% Tween-20. Membranes were 
exposed to X-ray film using the ECL Plus Detection reagent 
(Amersham Life Science, Inc., Piscataway, NJ, USA). E-Cadherin 
(1:1,000), β-actin (1:400), α-actinin (1:1,000), pan-cytokeratin 
(1:1,000), α-tubulin (1:2,000) and calnexin antibodies (1:10,000) 
were obtained from Santa Cruz Biotechnology, Santa Cruz, CA, 
USA and used for western blot analysis. Secondary antibody 
(Sigma) was used in proportion 1:5000. Densitometry levels for 
each blot were determined using calnexin as the loading control.
Immunohistochemistry. A549 cells (1x105) were plated onto 
glass coverslips and immediately treated with MM (1 µM) or 
GRN163L (1 µM). The cells were fixed in 3% paraformaldehyde 
for α-actinin and E-cadherin, and in microtubule stabilization 
buffer for F-actin, αβ tubulin and cytokeratin, following a 24-h 
incubation period. Fluorescein phalloidin, specific to F-actin, 
and mouse monoclonal antibodies against αβ tubulin (Santa 
Cruz Biotechnology), pan-cytokeratin (isoforms 1, 4, 5, 6, 8, 10, 
13, 18 and 19), α-actinin and E-cadherin (Sigma), were applied. 
FITC-conjugated goat anti-rabbit IgG for pan-cadherin and FITC-
conjugated goat anti-mouse IgG (Jackson ImmunoResearch 
Laboratories, Inc., West Grove, PA, USA) for the other cytoske-
letal proteins were used as secondary antibodies. All antibodies 
were diluted 1:100 in PBS and incubated for 90 min at 37˚C in a 
humidified chamber. Images were examined under a Carl Zeiss 
LSM 510 META Confocal Laser Scanning microscope (488-nm 
argon ion, 543-nm green helium neon, 633-nm red helium-neon 
laser lines) and consecutive optical sections were recorded and 
used for 3D image reconstruction.
Cell cycle analyses. Real-time PCR was used for cell cycle 
analyses; the A549 cells were incubated with GRN163L for 
24 h or up to 1 week. Total RNA was isolated from the control 
cells and GRN163L-treated cells using the RNeasy mini kit 
(Qiagen, Inc., USA, Valencia, CA, USA), according to the manu-
facturer's instructions. cDNA synthesis was performed using 
the DyNamo cDNA synthesis kit (Finnzymes, Espoo, Finland). 
Primers were designed using Primer Design sofware (version 
2.0; serial number: 52017. Copyright 1990, 91; Scientific and 
Educational Software) (Table I). Real-time PCR was performed 
using SYBR-Green (Finnzymes). Samples were heated to 94˚C 
for 5 min as the initial denaturation, followed by 40 cycles of 
denaturation at 95˚C for 30 sec, 55˚C for 30 sec, 72˚C for 30 sec 
and annealing̸extension at 75˚C for 5 min. A melt curve stage 
was added to analyze the PCR product. Cyclophilin A was 
used as an internal control gene to normalize for RNA quantity. 
The results were analyzed using the Bio-Rad iCycler-Techgene 
thermal cycler.
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Determination of MMP-2 expression. The correlation between 
telomerase inhibition and MMP-2 expression was evaluated by 
real-time PCR. To determine the effect of GRN163L on MMP-2 
expression, GRN163L (1 µM) was added to the medium 24 h 
after plating. After an additional 24 h, RNA was collected for 
real-time PCR from the control cells and GRN163L-treated cells 
using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). cDNA 
synthesis was then performed with M-MLV RT (Invitrogen). 
MMP-2 expression was assessed by real-time PCR which was 
performed using SYBR-Green (Applied Biosystems, Carlsbad, 
CA, USA). The primers used for real-time PCR are presented 
in Table II. Samples were heated to 95˚C for 3 min as initial 
denaturation, followed by 40 cycles of denaturation at 95˚C for 
3 sec, 58˚C for 20 sec, 72˚C for 5 sec and annealing̸extension 
at 95˚C for 1 min, 55˚C for 30 sec and 95˚C for 30 sec. A melt 
curve stage was added to analyze the PCR product. GAPDH 
was used as the internal control gene to normalize for RNA 
quantity.
Viral transduction. shRNA (0.5 µg), together with 0.5 µg of 
helper plasmids (0.2 µg pMD2G and 0.3 µg psPAX2) were 
transfected into 293FT cells with Effectene reagent (Qiagen). 
Viral supernatants were collected 48 h after the transfections 
and cleared through a 0.45-m filter. The A549 cells were trans-
fected with viral supernatants containing 2 µg̸ml polybrene 
(Sigma) and the successfully transfected cells were selected 
using puromycin.
Invasion/cell migration assay. A549 cells were treated with 
1 µM GRN163L for 24 h. The untreated and treated cells 
(1x105) were then plated in Matrigel™-coated invasion cham-
bers (BD Biosciences, San Jose, CA, USA) and processed 
according to the manufacturer's instructions. shMMP-2 
knockdown cells were used as a series of control cells. 
Chemoattractant was added to the lower chamber (below the 
membrane), and culture medium, containing 10% FBS, was 
used for the A549 cells. Cells were incubated for 22 h at 37˚C, 
in an atmosphere of 5% CO2. Cells were removed from the top 
chamber using cotton swabs, washed, then fixed and stained 
with 6% glutaraldehyde and 0.5% crystal violet for 30 min. The 
cells that migrated through to the bottom of the membrane and 
stained were counted by photographing the membrane under 
a microscope.
Results
GRN163L disrupts the organization of cytoskeletal elements. 
In order to investigate whether the rounding effect observed 
within 24 h in the GRN163L-treated A549 cells is related to 
any changes in the cytoskeleton, the key elements of cytoskel-
etal proteins were investigated using western blot analysis and 
immunohistochemical staining techniques.
Actin and tubulin are the major proteins of the cytoske-
leton, which determines the shape of the cell. The western blot 
analysis results demonstrated that actin and tubulin expres-
sion decreased following a 24-h treatment with GRN163L, 
when compared to the control and MM-treated cells (Fig. 1).
As an actin-binding protein, α-actinin plays multiple roles 
in different types of cells. In epithelial cells it is found along 
actin filament bundles and adherens-type junctions, where it 
is involved in the binding of actin to the cell membrane. We 
observed an approximate 2- to 3-fold increase in α-actinin 
expression in the cells treated with GRN163L for 24 h, 
compared to the control and MM-treated cells (Fig. 1).
In the untreated and MM-treated A549 cells, we observed 
an organization of dense actin filaments, exhibiting common 
Figure 1. Western blot analysis of the expression of β-actin, αβ-tubulin, 
α-actinin and pan-cytokeratin, in A549 cells either untreated (control), or 
treated with GRN163L (1 µM) or the mismatch (MM) (1 µM) oligonucleotides. 
Calnexin was used as the loading control.
Table I. Primer sequences for real-time PCR analyses of G1 phase genes.
Target Oligonucleotide sequences Base pairs GenBank accession no.
Cyclin D1 F: 5'-ATGAACTACCTGGACCGCTT-3' 142 NM_053056.2
 R: 5'-TCGGTGTAGATGCACAGCTT-3'
Cdk4 F: 5'-GACCAGGACCTAAGGACATA-3' 146 NM_000075.2
 R: 5'-GTTCTCTGGCTTCAGATCTC-3'
Cdk6 F: 5'-TTCACACCGAGTAGTGCATC-3' 122 NM_001259.5
 R: 5'-GAGGTTAGAGCCATCTGGAA-3'
Cyclophilin A F: 5'-AATGGCACTGGTGGCAAGTC-3' 219 NM_021130.3
 R: 5'-GCTCCATGGCCTCCACAATA-3'
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cytoplasmic dispersion, as detected by immunohistochemistry 
analyses. GRN163L treatment prior to cell attachment disrupted 
the cytoplasmic distribution of actin. In the GRN163L-treated 
cells, essentially all the actin filaments were displaced and 
concentrated along the cell membrane within 24 h. These results 
demonstrated that the decrease in actin expression, as well as 
significant changes in the morphological distribution of actin 
in the cell, were caused by the presence of GRN163L (Fig. 2).
Similar to the intracellular distribution of actin, extensive 
bundles of microtubules, which ‘radiate’ throughout the cyto-
plasm of A549 cells, was observed in the untreated control cells. 
GRN163L treatment altered the perinuclear and radial organiza-
tion of the tubulin cytoskeleton and microtubules were relocated 
toward the cell membrane, in a pattern similar to that of actin 
filaments (Fig. 2). The immunostaining results demonstrated 
that α-actinin protein was localized under the membrane, and 
was mostly colocalized with actin filaments (data not shown).
Intermediate filaments form homogeneous polar fibers 
within the cells and they are cell-type-dependent. Cytokeratins 
are the most common intermediate filaments found in epithe-
lial cells. Western blot analysis of cytokeratin expression 
did not demonstrate any significant difference between the 
GRN163L-treated and control cells (Fig. 1). By contrast, immu-
nohistochemical staining indicated that the cytokeratins were 
redistributed evenly throughout the cytoplasm in untreated 
control cells, whereas in the GRN163L-treated cells, the cyto-
keratins were localized to the cell periphery (Fig. 2).
Of note, GRN163L treatment resulted in significant loss of 
E-cadherin expression. Western blot analysis results demon-
strated a significant decrease in E-cadherin expression in A549 
Table II. Primer sequences for real-time PCR analyses of matrix metalloproteinase-2 (MMP-2).
Target Oligonucleotide sequences GenBank accession no.
MMP-2 F: 5'-GTATCCATCGCCATGCTCC-3' NM_004530
 R: 5'-AAGAACCAGATCACATACAGGATCA-3'
GAPDH F: 5'-GAGTCCACTGGCGTCTTC-3' NM_002046.3
 R: 5'-GCATTGCTGATGATCTTGAGG-3'
Figure 2. Effects of GRN163L and mismatch (MM) oligonucleotide on F-actin, tubulin, α-actinin and pan-cytokeratin filament organization in A549 cells. A549 
cells were plated on chamber slides in the presence of GRN163L (1 µM) and incubated for 24 h. Scale bars, 10 µm.
Figure 3. Western blot analysis of E-cadherin expression in GRN163L- (1 µM) 
and mismatch (MM) oligonucleotide (1 µM)-treated A549 cells. Calnexin was 
used as the loading control.
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cells within 24 h (Fig. 3). The immunohistochemical analysis 
results also demonstrated a decrease in E-cadherin expression 
at 24 h (Fig. 4).
GRN163L does not cause morphological changes and loss of 
cell adhesion in the cytoskeleton after thermal denaturation 
(heating for 5 min at 80˚C). After the A549 cells were plated on 
coverslips, GRN163L (1 µM) was heated for 5 min at 80˚C, then 
added to the cell culture medium. Following a 24-h incubation 
period, the cells were fixed and stained for actin, tubulin and 
E-cadherin. The structures of actin, tubulin and E-cadherin 
were not markedly altered in the cells treated with the pre-
heated GRN163L. Approximately 80% of these cells remained 
attached and exhibited morphological characteristics (Fig. 5) 
similar to the untreated control or MM-treated cells (data not 
shown). These results demonstrate that morphological changes 
and the loss of adhesion are specific to the oligonucleotide and 
GRN163L is ‘inactivated’ by heating for 5 min at 80˚C.
GRN163L decreases the expression of G1 phase cell cycle 
control genes. The morphologically altered or ‘rounded’ cells 
were unable to proliferate significantly while they were exposed 
to GRN163L treatment during the first 72 h. To elucidate the 
molecular mechanism behind this initial cell cycle arrest, we 
evaluated the mRNA levels of cyclin D1, Cdk4 and Cdk6, which 
are regulators of the G1 phase of the cell cycle, by real-time PCR. 
After plating the cells, GRN163L was added to the medium 
and the cells were collected following 72 h of incubation. No 
Figure 4. Effects of GRN163L and mismatch (MM) oligonucleotide on E-cadherin distribution. A549 cells were plated on chamber slides in the presence of 
GRN163L (1 µM) and incubated for 24 h. Scale bars, 10 µm.
Figure 5. F-actin, tubulin and E-cadherin distribution in the cells treated with GRN163L and thermally-inactivated GRN163L. Scale bars, 50 µm in F-actin 
and activated tubulin images and 10 µm in E-cadherin images.
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significant change in Cdk4 and Cdk6 mRNA expression levels 
was detected following 72 h of incubation with a single dose of 
GRN163L (data not shown). When the second set of cells was 
treated twice a week and collected for cell cycle analysis, a signifi-
cant reduction of cyclin D1, Cdk4 and Cdk6 mRNA expression 
levels was observed, compared to the untreated controls (Fig. 6).
GRN163L treatment decreases MMP-2 expression and invasion 
of A549 lung cancer cells through Matrigel. When MMP-2 
mRNA expression was determined by real-time PCR, a decrease 
in MMP-2 mRNA expression of ~40% was observed in the A549 
cells treated with GRN163L (Fig. 7). To determine whether this 
decrease was functional, we examined the motility/migration/
invasive ability of the A549 cells treated with GRN163L. The 
cells were exposed to GRN163L for 24 h prior to plating on 
Matrigel-coated invasion chambers; the cells were then allowed to 
migrate/invade for 22 h. As shown in Fig. 8, GRN163L treatment 
decreased the invasive ability of the A549 cells by ~50%, whereas 
the untreated cells were still able to invade. The results for the 
MM-treated control cells were similar to those of the untreated 
cells (data not shown). The MMP-2 knockdown efficiency was 
assessed using quantitative real-time PCR. The results were 
quantified following normalization to non-silencing shRNA. 
The percentage of MMP-2 shRNA knockdown cells was 28%. 
shMMP-2 knockdown cells were used as the negative control in 
the experiment (Fig. 8) demonstrating the significance of MMP-2 
for the migration through the Matrigel-coated membrane.
Discussion
Unregulated cell proliferation, escape from apoptosis, increase 
in tumor neovascularization (angiogenesis), migration, invasion 
and metastasis are all common features of various types of 
cancer (16). GRN163L is a telomerase template antagonist, that 
inhibits telomerase activity by binding to the template region 
of hTR. We discovered that GRN163L exerts additional effects, 
apart from the inhibition of telomerase, namely the disruption 
of cytoskeletal proteins, such as actin, tubulin, cytokeratin and 
α-actinin, as well as E-cadherin organization, and thus impairs 
cell adhesion and affects cell morphology. Using western blot 
analysis, we observed a significant decrease in actin, tubulin and 
E-cadherin expression in the GRN163L-treated cells, compared 
to the untreated control and MM oligonucleotide-treated cells 
(Fig. 2). Immunohistochemical staining also revealed that 
GRN163L disrupted the organization of 3 basic elements of 
the cytoskeleton: actin, tubulin and intermediate filaments. The 
altered cell morphology (i.e., rounding) observed in response to 
GRN163L treatment, may be a result of the disorganization of 
basic elements of the cytoskeleton, that are the key to sustaining 
the shape of the cell and structural scaffold. Of note, the MM 
control oligonucleotide (MM oligonucleotide sequence, 5'-Palm-
TAGGTGTAAGCAA; GRN163L oligonucleotide sequence, 
5'-Palm-TAGGGTTAGACAA) did not have any effect on cell 
morphology or cell adhesion (14). Since the MM control differs 
from GRN163L only by the lack of 3 contiguous guanine resi-
dues, it is possible that this motif is responsible for the altered 
cell morphology and adhesion phenotype upon treatment.
A similar reduction in migration and metastasis following 
treatment with GRN163L has previously been demonstrated in 
lung cancer cells using in vivo xenograft animal models (13,14), 
although the mechanisms underlying this effect were not 
elucidated in these studies. In this study, we demonstrate 
that the anti-adhesive effects of GRN163L, which may also 
contibute to the antimetastatic properties of this compound, 
are related to the disruption of cytoskeletal proteins, resulting 
in alterations in cell architecture and the intracellular reloca-
lization of cytoskeletal elements. Consistent with this finding, 
Goldblatt et al (18) demonstrated similar results in MDA-MB-
231 breast cancer cells; when GRN163L was added to the 
medium prior to cell attachment, it altered cell morphology, 
actin filament organization and focal adhesion formation.
Figure 6. Analysis of cyclin D1, Cdk6 and Cdk4 mRNA expression in untreated, 
mismatch (MM) oligonucleotide- and GRN163L-treated cells by real-time 
RT-PCR (n=3).
Figure 7. Analysis of MMP-2 mRNA expression in untreated, mismatch (MM) 
oligonucleotide- and GRN163L-treated cells by real-time RT-PCR (n=3).
Figure 8. Invasion of A549 cells treated with GRN163L. A549 cells were treated 
with 1 µM GRN163L for 24 h, then plated in Matrigel-coated invasion chambers 
for 22 h. Knockdown cells (shMMP-2) were used as the negative control (n=2).
INTERNATIONAL JOURNAL OF ONCOLOGY  42:  1709-1715,  2013 1715
Shin et al (19) demonstrated that actin disruption induced 
the phosphorylation of H2AX, a well-known double-strand 
break (DSB) marker, leading to G2 phase arrest and conse-
quently resulting in the apoptosis of MCF-7 cancer cells. Based 
on these data, the authors suggested that actin disruption may 
be a potential candidate in the development of anticancer thera-
pies for human cancers. Microtubules are also considered as 
important cellular targets for anticancer therapy, due to their 
key role in mitosis. Microtubule inhibitors such as taxanes, 
vinca alkaloids and epothilones, stabilize or destabilize micro-
tubules, thereby suppressing microtubule dynamics required 
for proper mitotic function, effectively blocking cell cycle 
progression and resulting in apoptosis (20).
E-cadherin is critical for epithelial cell-cell adhesion. It 
is a well-known fact that, in order to be able to metastasize, 
cancer cells require attachment to a solid surface, in addition 
to their ability to proliferate and migrate (16). Our western blot 
analysis and immunostaining results support the hypothesis 
that the GRN163L-induced phenotypic changes may be attrib-
uted to alterations in the structural function of the treated cells. 
It is also possible that the downregulation of E-cadherin may 
reduce the attachment of cancer cells. In this case, the loss of 
adhesion may be due to the change in E-cadherin expression, 
resulting in the inability of cancer cells to attach. Additionally, 
the unattached ‘rounded’ cells lost their proliferative capacity 
and were reversibly arrested in the G1 phase of the cell cycle.
It has previously been reported that in NSCLC, the level 
of MMP-2 is increased in tumor cells, as well as in the peri-
tumoral stromal tissues. Furthermore, MMP-2 expression has 
been reported to be an indicator of poor prognosis, associated 
with a worse overall survival (21). In this study, we demon-
strated that GRN163L treatment led to a moderate decrease 
in MMP-2 expression in A549 lung cancer cells. Additionally, 
the migration/invasive ability of A549 cells through Matrigel 
decreased following a 24-h exposure to 1 µM of GRN163L. 
These rapid effects of GRN163L were independent of 
telomerase activity and telomere length. In this study, to our 
knowledge, we demonstrate for the first time that GRN163L 
treatment decreases the migration̸invasive capacity of tumor 
cells, possibly through the downregulation of MMP-2. These 
data suggest that GRN163L treatment following surgery and 
primary chemo̸radiation therapy may prevent the invasion of 
residual cancer cells in NSCLC patients.
In conclusion, in the present study, we demonstrated that 
GRN163L altered the cell morphology due to the disruption 
of cytoskeletal elements and led to the loss of cell adhesion 
by decreasing E-cadherin expression. The cells treated with 
GRN163L were arrested in the G1 phase of the cell cycle. 
Furthermore, GRN163L inhibited the migration̸invasion 
of A549 lung cancer cells through the downregulation of 
MMP-2. Based on these in vitro data, we hypothesized that 
residual circulating cancer cells present in the bloodstream, 
i.e., after tumor debulking surgery or chemotherapy, may be 
unable to attach and proliferate in the presence of GRN163L, 
due to the loss of adhesion properties and proliferative ability. 
Thus, the addition of a telomerase template antagonist to the 
anticancer therapy regimen may not only lead to a decrease 
in the growth of the primary tumor mass, but may also 
reduce the formation of distant metastases due to its non-
telomerase-related effects.
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